MICROBIOLOGY Correction for “A comparative genomics approach identifies contact-dependent growth inhibition as a virulence determinant,” by Jonathan P. Allen, Egon A. Ozer, George Minasov, Ludmilla Shuvalova, Olga Kiryukhina, Karla J. F. Satchell, and Alan R. Hauser, which was first published March 10, 2020; 10.1073/pnas.1919198117 (Proc. Natl. Acad. Sci. U.S.A. 117, 6811–6821).
The authors note that, due to a printer’s error, Table 1 is missing the rows for AGEv14 and AGEv15. The corrected table appears below.
Table 1.
Summary of investigated AGEs
| AGE | Isolates* | Features | Context† | Mutant background‡ | Dose§ | n¶ | P level# |
| AGEv | |||||||
| AGEv1 | 14 | Glucan synthesis, fatty acid metabolism | GI | PABL012 | 6.5 | 10 | <0.0001 |
| PABL057 | 6.2 | 10 | 0.0010 | ||||
| AGEv2 | 16 | Phage-related, hypothetical | Phage | PABL026 | 7.0 | 10 | <0.0001 |
| PABL049 | 6.7 | 10 | <0.0001 | ||||
| AGEv3 | 8 | Transposon, hypothetical | Tn | PABL016 | 6.6 | 15 | 0.5755 |
| AGEv4 | 5 | Restriction modification | Tn | PABL007 | 7.0 | 10 | 0.0017 |
| AGEv5 | 15 | Substrate transport & metabolism | PABL049 | 6.6 | 10 | 0.0002 | |
| PABL070 | 6.8 | 10 | 0.0002 | ||||
| AGEv6 | 9 | Phage-related, hypothetical | Phage | PABL012 | 6.6 | 20 | <0.0001 |
| PABL049 | 6.5 | 10 | 0.0085 | ||||
| AGEv7 | 49 | Phage-related, hypothetical | Phage | PABL012 | 6.5 | 15 | <0.0001 |
| PABL049 | 6.9 | 10 | <0.0001 | ||||
| AGEv8 | 3 | RHS-containing gene | PMT | PABL016 | 6.6 | 15 | 0.0008 |
| AGEv9 | 10 | Phage-related | Phage | PABL012 | 6.6 | 15 | 0.0164 |
| PABL049 | 6.7 | 10 | 0.0139 | ||||
| AGEv10 | 4 | RND family heavy metal efflux proteins | PABL016 | 6.8 | 15 | 0.4811 | |
| PABL068 | 5.8 | 10 | 0.3933 | ||||
| AGEv11 | 2 | Phage-related | Phage | PABL012 | 6.5 | 30 | 0.0001 |
| AGEv12 | 82 | ICE proteins | GI | PABL012 | 6.6 | 15 | 0.0008 |
| PABL049 | 6.7 | 10 | <0.0001 | ||||
| AGEv13 | 18 | Autotransporter protein | PABL083 | 6.5 | 20 | 0.5694 | |
| PABL107 | 6.5 | 30 | 0.0526 | ||||
| AGEv14 | 10 | DnaB, DnaC (phage replication) | Phage | PABL012 | 6.6 | 10 | <0.0001 |
| PABL013 | 6.5 | 15 | 0.2061 | ||||
| AGEv15 | 10 | Contact-dependent growth inhibition | PMT | PABL017 | 6.8 | 20 | 0.0041 |
| AGEx | |||||||
| AGEx1 | 14 | Phage related | Phage | PABL012 | 6.5 | 10 | 0.6789 |
| AGEx2 | 69 | Helicase, hypothetical | Phage | PABL012 | 6.5 | 10 | 0.2059 |
| AGEx3 | 48 | Peptide synthase, hypothetical | PABL016 | 6.7 | 10 | 0.2247 | |
| AGEx4 | 35 | Hypothetical | PABL012 | 6.5 | 10 | 0.4328 | |
| AGEx5 | 32 | Hypothetical | PABL049 | 6.7 | 10 | 0.2402 | |
Number of isolates in which the AGE was observed.
Genomic context in which the AGE was observed. Abbreviations include pKLC102-like genomic island (GI), transposon (Tn), polymorphic toxin (PMT), or predicted prophage (Phage).
PABL isolate in which the AGE mutation was constructed.
Dose for mouse bacteremia infection (log10 CFU).
Number of mice infected.
Log-rank test.